TherapeuticsMD, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TherapeuticsMD, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.76M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | $1.30M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $69.96M | Mar 29, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $69.96M | Apr 7, 2023 |
| FY2021 | Dec 31, 2021 | $18.68M | Mar 23, 2022 |
| FY2021 | Sep 30, 2021 | $25.41M | Mar 23, 2022 |
| FY2021 | Jun 30, 2021 | $23.00M | Mar 23, 2022 |
| FY2021 | Mar 31, 2021 | $19.87M | Mar 23, 2022 |
| FY2021 | Dec 31, 2020 | $22.58M | Mar 23, 2022 |
| FY2021 | Sep 30, 2020 | $19.34M | Mar 23, 2022 |
| FY2021 | Jun 30, 2020 | $10.70M | Mar 23, 2022 |
| FY2021 | Mar 31, 2020 | $12.25M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $15.90M | Mar 4, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $4.13M | Feb 23, 2018 |
| FY2017 | Sep 30, 2017 | $4.42M | Feb 23, 2018 |
| FY2017 | Jun 30, 2017 | $4.25M | Feb 23, 2018 |
| FY2017 | Mar 31, 2017 | $3.99M | Feb 23, 2018 |
| FY2016 | Dec 31, 2016 | $4.49M | Feb 28, 2017 |
| FY2016 | Sep 30, 2016 | $5.54M | Feb 28, 2017 |
| FY2016 | Jun 30, 2016 | $4.40M | Feb 28, 2017 |
| FY2016 | Mar 31, 2016 | $4.93M | Feb 28, 2017 |
| FY2015 | Dec 31, 2015 | $5.63M | Feb 26, 2016 |
| FY2015 | Sep 30, 2015 | $5.19M | Feb 26, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.30M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $68.57M | Mar 29, 2024 |
| FY2021 | Dec 31, 2021 | $13.94M | Mar 23, 2022 |
| FY2021 | Sep 30, 2021 | $20.12M | Mar 23, 2022 |
| FY2021 | Jun 30, 2021 | $18.87M | Mar 23, 2022 |
| FY2021 | Mar 31, 2021 | $15.18M | Mar 23, 2022 |
| FY2021 | Dec 31, 2020 | $17.00M | Mar 23, 2022 |
| FY2021 | Sep 30, 2020 | $16.06M | Mar 23, 2022 |
| FY2021 | Jun 30, 2020 | $6.30M | Mar 23, 2022 |
| FY2021 | Mar 31, 2020 | $9.54M | Mar 23, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($569.0K) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($2.18M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($10.28M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $112.00M | Mar 29, 2024 |
| FY2021 | Dec 31, 2021 | ($42.96M) | Mar 23, 2022 |
| FY2021 | Sep 30, 2021 | ($47.42M) | Mar 23, 2022 |
| FY2021 | Jun 30, 2021 | ($42.65M) | Mar 23, 2022 |
| FY2021 | Mar 31, 2021 | ($39.38M) | Mar 23, 2022 |
| FY2021 | Dec 31, 2020 | ($42.09M) | Mar 23, 2022 |
| FY2021 | Sep 30, 2020 | ($32.61M) | Mar 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.39M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($6.11M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($8.52M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.19M | Mar 29, 2024 |
| FY2021 | Dec 31, 2021 | ($35.39M) | Mar 23, 2022 |
| FY2021 | Sep 30, 2021 | ($39.92M) | Mar 23, 2022 |
| FY2021 | Jun 30, 2021 | ($35.18M) | Mar 23, 2022 |
| FY2021 | Mar 31, 2021 | ($29.28M) | Mar 23, 2022 |
| FY2021 | Dec 31, 2020 | ($34.61M) | Mar 23, 2022 |
| FY2021 | Sep 30, 2020 | ($24.97M) | Mar 23, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $7.09M | Mar 23, 2022 |
| FY2021 | Dec 31, 2020 | $10.43M | Mar 23, 2022 |
| FY2021 | Dec 31, 2019 | $19.79M | Mar 23, 2022 |
| FY2020 | Dec 31, 2018 | $27.30M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $33.85M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $53.94M | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $72.04M | Feb 23, 2018 |
| FY2016 | Dec 31, 2014 | $43.22M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $13.55M | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $4.49M | Mar 12, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.74M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | $8.90M | Mar 27, 2025 |
| FY2020 | Dec 31, 2020 | $192.96M | Mar 4, 2021 |
| FY2020 | Dec 31, 2019 | $174.11M | Mar 4, 2021 |
| FY2020 | Dec 31, 2018 | $115.99M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $57.70M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $51.35M | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $28.72M | Feb 23, 2018 |
| FY2016 | Dec 31, 2014 | $22.12M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $19.01M | Feb 26, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | ($142.69M) | Mar 23, 2022 |
| FY2021 | Dec 31, 2020 | ($159.47M) | Mar 23, 2022 |
| FY2021 | Dec 31, 2019 | ($165.72M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2018 | ($106.81M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | ($76.16M) | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | ($69.14M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | ($79.04M) | Feb 23, 2018 |
| FY2016 | Dec 31, 2014 | ($45.52M) | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | ($20.77M) | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | ($12.74M) | Mar 12, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $34.0K | Apr 7, 2023 |
| FY2021 | Dec 31, 2020 | $207.0K | Mar 23, 2022 |
| FY2021 | Dec 31, 2019 | $2.45M | Mar 23, 2022 |
| FY2020 | Dec 31, 2018 | $217.0K | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $61.8K | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $396.2K | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $165.3K | Feb 23, 2018 |
| FY2016 | Dec 31, 2014 | $31.0K | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $40.8K | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $66.4K | Mar 12, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.66M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $38.82M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $43.31M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $90.46M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $169.47M | Apr 7, 2023 |
| FY2021 | Dec 31, 2020 | $181.61M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $265.99M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $211.98M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $143.23M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $142.47M | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.78M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $11.45M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $14.02M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $55.32M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $263.09M | Apr 7, 2023 |
| FY2021 | Dec 31, 2020 | $305.61M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $256.78M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $114.46M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $13.32M | Feb 27, 2019 |
| FY2013 | Dec 31, 2013 | $7.32M | Mar 5, 2014 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.88M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $27.37M | Apr 1, 2026 |
| FY2025 | Dec 31, 2023 | $29.29M | Apr 1, 2026 |
| FY2024 | Dec 31, 2022 | $35.14M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | ($93.62M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | ($124.00M) | Apr 7, 2023 |
| FY2021 | Dec 31, 2019 | $9.20M | Mar 23, 2022 |
| FY2021 | Dec 31, 2018 | $97.52M | Mar 23, 2022 |
| FY2020 | Dec 31, 2017 | $129.91M | Mar 4, 2021 |
| FY2019 | Dec 31, 2016 | $127.49M | Feb 24, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($952.39M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($951.82M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($949.64M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($939.36M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($1.05B) | Apr 7, 2023 |
| FY2021 | Dec 31, 2020 | ($878.95M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($695.42M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($519.28M) | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | ($386.66M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($309.70M) | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.06M | Mar 27, 2025 |
| FY2024 | Dec 31, 2023 | $4.33M | Mar 27, 2025 |
| FY2011 | Dec 31, 2011 | $126.4K | Mar 27, 2012 |
| FY2011 | Dec 31, 2010 | $422.9K | Mar 27, 2012 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $188.27M | Apr 7, 2023 |
| FY2021 | Dec 31, 2020 | $237.70M | Mar 23, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 12 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (21) | Apr 7, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 11 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (21) | Apr 7, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.57M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 11.53M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 11.53M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 9.50M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 8.60M | Apr 7, 2023 |
| FY2021 | Dec 31, 2020 | 299.77M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | 271.18M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 240.46M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | 216.43M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 196.69M | Feb 23, 2018 |